Fifty years of tobacco carcinogenesis research: From mechanisms to early detection and prevention of lung cancer

Cancer Prevention Research

Volumn 7, Issue 1, 2014, Pages 1-8

  Hecht, Stephen S ^a   Szabo, Eva ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; 4 BIPHENYLAMINE; ACETYLSALICYLIC ACID; BENZO[A]PYRENE; BIOLOGICAL MARKER; CARCINOGEN; CATECHIN; CIGARETTE SMOKE; DIMETHYLNITROSAMINE; ELECTRONIC CIGARETTE; ERLOTINIB; ETHYLENE OXIDE; ILOPROST; INOSITOL; ISOTHIOCYANIC ACID DERIVATIVE; METFORMIN; NICOTINE; NITROSONORNICOTINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIOGLITAZONE;

BRONCHUS CANCER; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CARCINOGEN DNA INTERACTION; CARCINOGENESIS; CAUSE OF DEATH; CHEMICAL CARCINOGENESIS; CLINICAL TRIAL (TOPIC); COCARCINOGENESIS; DNA ADDUCT; EARLY DIAGNOSIS; GENE EXPRESSION; GENE MUTATION; GOVERNMENT REGULATION; HIGH RISK POPULATION; HUMAN; INFLAMMATION; LUNG CANCER; MASS SPECTROMETRY; METABOLIC ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SMOKING; SMOKING CESSATION PROGRAM; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TOBACCO; TUMOR PROMOTION;

BIOMEDICAL RESEARCH; CARCINOGENESIS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LUNG NEOPLASMS; SMOKING; TOBACCO; UNITED STATES;

EID: 84892406456     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0371     Document Type: Review

References (52)

1. American Cancer Society. Cancer facts and figures 2001. Atlanta, GA: American Cancer Society; 2001. p. 29-32.
2. Centers for Disease Control and Prevention (CDC). Current cigarette smoking among adults-United States, 2011. MMWR Morb Mortal Wkly Rep 2012;61: 889-94.
3. Office of the Surgeon General. Cigarette Smoking in the United States, 1950-1978. In: Pinney JM editor, Smoking and health: a report of the surgeon general. Washington, DC: United States Public Health Service, Office on Smoking and Health; 1979. p. A1-A29. Available from: (http://profiles.nlm.nih.gov/ps/ retrieve/ResourceMetadata/NNBCPH).
4. Surveillance Research Program NCI. Fast Stats: an interactive tool for access to SEER cancer statistics. 2013. [accessed 2013 Jul 24]. Available from: http://seer.cancer.gov/faststats.
5. Viswanath K, Herbst RS, Land SR, Leischow SJ, Shields PG Writing Committee for the AACR Task Force on Tobacco and Cancer. Tobacco and cancer: an American Association for Cancer Research Policy Statement. Cancer Res 2010;70: 3419-30.
6. Hanna N, Mulshine J, Wollins DS, Tyne C, Dresler C. Tobacco cessation and control a decade later: American Society of Clinical Oncology Policy Statement Update. J Clin Oncol 2013;31: 3147-57.
7. Rodgman A, Perfetti T. The chemical components of tobacco and tobacco smoke. Boca Raton, FL: CRC Press; 2009. p. 1483-784.
8. International Agency for Research on Cancer. Tobacco smoke and involuntary smoking. In IARC Monographs on the evaluation of carcinogenic risks to humans, Vol. 83. Lyon, France: IARC; 2004. p. 53-1187.
9. Hecht SS. Research opportunities related to establishing standards for tobacco products under the Family Smoking Prevention and Tobacco Control Act. Nicotine Tob Res 2012;14: 18-28.
10. Miller JA. Research in chemical carcinogenesis with Elizabeth Miller-a trail of discovery with our associates. Drug Metab Dispos 1994;26: 1-36.
11. Penning TM. Chemical carcinogenesis. New York, NY: Humana Press, 2011.
12. Phillips DH, Venitt S. DNA and protein adducts in human tissues resulting from exposure to tobacco smoke. Int J Cancer 2012;131: 2733-53.
13. United States Department of Health and Human Services. How tobacco smoke causes disease: the biology and behavioral basis for smoking- attributable disease: a report of the surgeon general (Ch. 5). Washington, DC: U.S. Department of Health and Human Services; 2010.
14. Hecht SS. Lung carcinogenesis by tobacco smoke. Int J Cancer 2012;131: 2724-32.
15. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455: 1069-75.
16. Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, Stinson J, et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010;465: 473-7.
17. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012;150: 1121-34.
18. Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M. Tobacco smoke promotes lung tumorigenesis by triggering IKKb- and JNK1- dependent inflammation. Cancer Cell 2010;17: 89-97.
19. Strasser AA, Benowitz NL, Pinto AG, Tang KZ, Hecht SS, Carmella SG, et al. Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer Epidemiol Biomarkers Prev 2011; 20: 234-8.
20. Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob P. Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res 2003;5: 621-4.
21. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer, and peripheral arterial disease. Nature 2008;452: 638-42.
22. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, et al. Genomewide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008;40: 616-22.
23. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008;452: 633-7.
24. Hecht SS, Yuan J-M, Hatsukami DK. Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. Chem Res Toxicol 2010;23: 1001-8.
25. Shafey O, Eriksen MP, Ross H, Mackay J. The tobacco atlas. 3rd ed. Atlanta, GA: American Cancer Society and World Lung Foundation; 2009. p. 19-33.
26. U.S. Food and Drug Administration. Harmful and potentially harmful constituents in tobacco products and tobacco smoke; established list. Fed Regist 2012;77: 20034-7.
27. Fiore MC, Jaen CR, Baker TB for the Guideline Panel. Treating Tobacco Use and Dependence, 2008 Update. U.S. Department of Health and Human Services, Public Health Service, May 2008, 257 pages; available at books.google.com.
28. Spitz MR, Etzel CJ, Dong Q, Amos CI, Wei Q, Wu X, et al. An expanded risk prediction model for lung cancer. Cancer Prev Res 2008;1: 250-4.
29. Cassidy A, Myles JP, van Tongeren M, Page RD, Liloglou T, Duffy SW, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 2008;98: 270-6.
30. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003;95: 470-8.
31. Cronin KA, Gail MH, Zou Z, Bach PB, Virtamo J, Albanes D. Validation of a model of lung cancer risk prediction among smokers. J Natl Cancer Inst 2006;98: 637-40.
32. Tammemagi CM, Pinsky PF, Caporaso NE, Kvale PA, Hocking WG, Church TR, et al. Lung cancer risk prediction: prostate, lung, colorectal and ovarian cancer screening trial models and validation. J Natl Cancer Inst 2011;103: 1058-68.
33. Hecht SS. Carcinogenicity studies of inhaled cigarette smoke in laboratory animals: old and new. Carcinogenesis 2005;26: 1488-92.
34. Hecht SS, Kassie F, Hatsukami DK. Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers. Nat Rev Cancer 2009;9: 476-88.
35. NLST Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Eng J Med 2011;365: 395-409.
36. Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, et al. Screening by chest radiograph and lung cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) randomized trial. JAMA 2011;306: 1865-7.
37. Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, et al. Targeting of low-dose CT screening according to the risk of lung cancer death. N Eng J Med 2013;369: 245-54.
38. Maisonneuve P, Bagnardi V, Bellomi M, Spaggiari L, Pelosi G, Rampinelli C, et al. Lung cancer risk prediction to select smokers for screening CT-a model based on the Italian COSMOS trial. Cancer Prev Res 2011;4: 1778-89.
39. McWilliams A, Tammemagi MC, Mayo JR, Roberts H, Liu G, Soghrati K, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Eng J Med 2013;369: 910-9.
40. Brothers JF, Hijazi K, Mascaux C, El-Zein RA, Spitz MR, Spira A. Bridging the clinical gaps: genetic, epigenetic and transcriptomic bioamrkers for the early detection of lung cancer n the post-National Lung Screening Trial era. BMC Med 2013;11:168.
41. Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL, Massion PP. The state of molecular biomarkers fo rthe early detection of lung cancer. Cancer Prev Res 2012;5:992-1006.
42. Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, et al. Airway epithelial gene expresison in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 2007;13: 361-6.
43. Sridhar S, Schembri F, Zeskind J, Shah V, Gustafson AM, Steiling K, et al. Smoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium. BMC Genomics 2008;9:259.
44. Roy HK, Subramanian H, Damania d, Hensing TA, Rom WN, Pass IH, et al. Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. Cancer Res 2010;70: 7748-54.
45. Saccomanno G, Archer VE, Auerbach O, Saunders RP, Brennan LM. Development of carcinoma of the lung as reflected in exfoliated cells. Cancer 1974;33: 256-70.
46. Auerbach O, Stout AP, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N Engl J Med 1961;265: 253-67.
47. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow C, Meade TW. Effect of daily aspirinon long-termrisk ofdeath due tocancer: analysis of individual patient data from randomised trials. Lancet 2011;377: 31-41.
48. Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, et al.Phosphoinositide3-kinase (PI3K)pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3Kinhibitors in lung cancer preclinical models. Clin Cancer Res 2012;18: 6771-83.
49. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333: 1157-60.
50. Gustafson AM, Soldi R, Anderlind C, Scholand MB, Qian J, Zhang X, et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med 2010;2:26ra25.
51. Keith R, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res 2011;4: 793-802.
52. Nemenoff RA, Weiser-Evans M, Winn RA. Activation and molecular targets of peroxisome proliferator-activated receptor-g ligands in lung cancer. PPAR Res 2008;2008:156875.